Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANETT: Neoadjuvant TAK-228 + Tamoxifen in ER+/HER2- Breast Cancer
NCT02988986Phase 2Completed
- Sponsor
- Houston Methodist Research Institute
- Start
- Apr 2017
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sapanisertib in breast cancer, sponsored by Houston Methodist Research Institute. Primary endpoint: Ki67 Expression at 6 weeks. Started Apr 2017; status: completed.
02
Drugs
sapanisertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02988986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02988986.